Home All Products GLP 1 Cagrilintide | RTA
GLP 1 Cagrilintide | RTA
GLP 1 Cagrilintide | RTA

GLP 1 Cagrilintide | RTA

The Cagrilintide / RTA Combination provides a dual-mechanism strategy for weight management and metabolic health.

  • Cagrilintide – a long-acting amylin analog (half-life ~165 hours) that enhances satiety, slows gastric emptying, and suppresses postprandial glucagon via brainstem amylin receptor activation.

  • RTA – a triple agonist of GLP-1, GIP, and glucagon receptors (half-life ~6 days), promoting insulin secretion, hepatic fat oxidation, appetite suppression, and energy expenditure.

Together, they target both homeostatic and hedonic eating pathways, improve glucose regulation, and drive fat loss through complementary metabolic mechanisms. For research use only. Not for human or veterinary consumption. Not intended for diagnostic or therapeutic applications . This product is not classified under U.S. DEA List I or List II chemical regulations. No DEA registration or reporting requirements apply.

  1. Jastreboff AM, et al. Efficacy and safety of retatrutide, a novel GLP-1, GIP, and glucagon receptor agonist for weight management in adults with obesity: A systematic review and meta-analysis. Obesity Medicine. 2025;15:100523. doi:10.1016/j.obmed.2025.100523
  2. Enebo LB, et al. Cagrilintide: A Long-Acting Amylin Analog for the Treatment of Obesity. Obesity. 2023;31(2):296-308. doi:10.1002/oby.23679
  3. Rosenstock J, et al. Retatrutide, a GIP, GLP-1 and glucagon receptor agonist, for people with type 2 diabetes: a randomised, double-blind, placebo and active-controlled, phase 2 trial conducted in the USA. Lancet. 2023;402(10401):529-544. doi:10.1016/S0140-6736(23)01053-X
  4. Lau DCW, et al. Cagrilintide lowers bodyweight through brain amylin receptors 1 and 3. Nat Med. 2025;31(7):1823-1835. doi:10.1038/s41591-025-02987-4
  5. Sachs S, et al. Combined GLP-1 Receptor Agonist and Amylin Analogue Treatment in Individuals With Type 1 Diabetes and Obesity: A Case Series. J Clin Endocrinol Metab. 2023;108(8):e642-e647. doi:10.1210/clinem/dgad228
  • Superior Weight Reduction: Clinical data suggest additive benefit vs monotherapy (Cagrilintide ~10.8%; Retatrutide up to 24%).
  • Dual Appetite Suppression: Amylin-mediated satiety + GLP-1/GIP/glucagon receptor effects.
  • Improved Glucose Regulation: Insulinotropic effects of Retatrutide + glucagon suppression from Cagrilintide.
  • Increased Energy Expenditure: Enhanced fatty acid oxidation and thermogenesis.
  • Gastric Emptying Delay: promoting satiety and postprandial glucose control.
  • Metabolic Flexibility: Enhanced fat utilization and energy partitioning.
  • Liver Fat Reduction: Up to 80% reduction in NAFLD markers with Retatrutide, supported by amylin synergy.
  • Cardiovascular Benefit: Potential improvements in blood pressure, lipids, and inflammation.
  • Hormonal Synergy: Targeting multiple endocrine pathways for comprehensive metabolic support.
  • Potential Diabetes Remission: Through insulin sensitization, glucagon suppression, and beta-cell support.

$570.00

Per Unit
Out of stock

Free Shipping on All Orders $1000+